Influenza Clinical Trial
— LIfTOfficial title:
A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older.
Verified date | February 2013 |
Source | Liquidia Technologies, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study is designed to evaluate the safety, tolerability, and immune response of LIQ001 mixed with a commercially available seasonal influenza vaccine (Fluzone) in two populations of subjects; healthy adult subjects 18 to 49 years of age and healthy elderly subjects 65 years of age or older.
Status | Completed |
Enrollment | 152 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age 18 to 49 years (Cohort 1) and age 65 or above (Cohort 2) - For subjects 18 to 49 years of age: in good health as determined by medical history, physical examination, and the clinical judgment of the Principal Investigator (PI) - For subjects 65 years of age and older: in stable good health as determined by medical history, physical examination, and the clinical judgment of the PI - Live in the community (including assisted living) - Available for duration of study (1 year) - If female, no child-bearing potential or using appropriate measures to prevent pregnancy - Negative urine pregnancy test for women presumed to be of child-bearing potential within 24 hours of vaccination - Be eligible for screening - Provide informed consent - Have working phone for contact by the study site personnel Exclusion Criteria: - Known allergy to eggs or any other component of Fluzone (including natural latex) or inactivated influenza vaccines or the investigational vaccine - Received seasonal influenza or H1N1 vaccine in last 6 months - A diagnosis of influenza within the previous 12 months - Received any licensed vaccine within the past 1 month - Receiving nursing home or equivalent care - For women, breast-feeding or planning to become pregnant during the first three months post-vaccination - Chronic administration of immunosuppressant(s) or other medication that modifies immune function - Confirmed immunodeficiency syndrome or disease - Significant cardiovascular disease including class 3 or 4 congestive heart failure, recent history (last 6 months) of acute myocardial infarction, coronary artery bypass surgery or stent placement, unstable angina, uncontrolled arrhythmia, and for subjects 65 years of age and older, a resting heart rate greater than 100 bpm - Hypertension that is not well controlled by medication in the judgment of the investigator or is more than 150/95 at enrollment - Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws - Medically significant chronic lung disease, e.g., requiring chronic steroid treatment (oral doses >10 mg/day) - Asthma that is severe, unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral, intravenous, or high dose inhaled corticosteroids (mild or intermittent asthma treated with inhaled steroids is acceptable) - Medically significant acute or progressive hepatic disease - Medically significant acute or progressive renal disease - Diabetes mellitus type 2 not under pharmacological control - A diagnosis of cancer with active treatment within the previous 5 years (except for a localized basal cell carcinoma of the skin) - History of autoimmune/inflammatory conditions (e.g., rheumatoid arthritis and diabetes mellitus type 1) - Medically significant acute or progressive neurological disease. - Seizure disorder that has required treatment within the last 3 years - History of Guillain-Barre Syndrome (GBS) - Administration of blood products, immunoglobulin, or investigational vaccine in the 3 months prior to immunization in this study - Use of investigational product (other than blood, immunoglobulin, or vaccine) in the past 60 days - Seropositive for HCV, HIV or positive for HBsAg - History of excessive alcohol use, drug abuse, or significant psychiatric illness - Unable to complete informed consent - Abnormal laboratory assessment meeting criteria for a mild, moderate, or severe adverse event - Any other condition or circumstance which, in the opinion of the PI, poses an unacceptable risk for participation in the study - Inability to operate and answer a telephone and lack of access to telephone - Temporary Exclusion Criteria: Presence of an oral temperature =99.5°F, and/or signs and symptoms of an acute infectious respiratory illness within 3 days prior to vaccination |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Accelovance - Melbourne | Melbourne | Florida |
Lead Sponsor | Collaborator |
---|---|
Liquidia Technologies, Inc. | Accelovance, Children's Hospital Medical Center, Cincinnati |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The rate of Adverse Events attributable to each of the doses of LIQ001 mixed with Fluzone compared to Fluzone alone. | 35 days post-vaccination | No | |
Secondary | HAI response (Geometric Mean Titer) of each of the doses of LIQ001 mixed with Fluzone compared to the Fluzone alone response. | 21 days post-vaccination | No | |
Secondary | HAI response (Percent with HAI titer greater than or equal to 1:40) of each of the doses of LIQ001 mixed with Fluzone compared to the Fluzone alone response. | 21 days post-vaccination | No | |
Secondary | HAI response (Seroconversion rate) of each of the doses of LIQ001 mixed with Fluzone compared to the Fluzone alone response. | 21 days post-vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |